Subtype
Colorectal Carcinoma
CI-CAN-00005005CRCExplore in graph →
344 active trials5 approved drugs22 evidence items
- NCIt
- C2955
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005005CRCExplore in graph →
Clinical trials
1,010 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (127)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02713373 | Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 45 | Roswell Park Cancer InstituteOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT03781778 | Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors | terminated | Phase 2 | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT03965845 | A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 53 | Calithera Biosciences, IncINDUSTRY | 1 | Sep 19, 2022 | clinicaltrials |
| NCT05091528 | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers | terminated | Phase 1 / Phase 2 | 2 | Silverback TherapeuticsINDUSTRY | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05406206 | Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy | unknown | Phase 2 | 27 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 6, 2022 | clinicaltrials |
| NCT03332498 | Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers | completed | Phase 1 / Phase 2 | 40 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT05239650 | Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC | not yet recruiting | Phase 2 | 50 | Shanghai Henlius BiotechINDUSTRY | 0 | May 3, 2022 | clinicaltrials |
| NCT03403634 | Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver | completed | Phase 2 | 19 | Roswell Park Cancer InstituteOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT03875313 | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | Calithera Biosciences, IncINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT04119830 | Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Feb 8, 2022 | clinicaltrials |
| NCT02292758 | Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 36 | Academic and Community Cancer Research UnitedOTHER | 1 | Jan 31, 2022 | clinicaltrials |
| NCT03050814 | Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 | terminated | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 20, 2021 | clinicaltrials |
| NCT04418895 | Neoadjuvant Therapy for Localized Rectal Adenocarcinoma | withdrawn | Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2021 | clinicaltrials |
| NCT02319304 | Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed Rectal Adenocarcinoma(GCC 1314) | terminated | Phase 2 | 3 | University of Maryland, BaltimoreOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT04582981 | Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer | unknown | Phase 2 | 136 | Fudan UniversityOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT04109755 | Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer(PEMREC) | recruiting | Phase 2 | 25 | University Hospital, GenevaOTHER | 1 | Sep 30, 2021 | clinicaltrials |
| NCT00040599 | Safety Study of 90Y-hMN14 to Treat Colorectal Cancer | completed | Phase 1 / Phase 2 | 72 | Gilead SciencesINDUSTRY | 5 | Aug 19, 2021 | clinicaltrials |
| NCT00041652 | Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer | completed | Phase 1 / Phase 2 | 30 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT04988191 | Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer | unknown | Phase 1 / Phase 2 | 44 | Peking UniversityOTHER | 1 | Aug 3, 2021 | clinicaltrials |
| NCT02393755 | Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 42 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT03142516 | FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status(OPALO) | completed | Phase 2 | 20 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT03576963 | Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT02811497 | Study of Azacitidine and Durvalumab in Advanced Solid Tumors(METADUR) | completed | Phase 2 | 28 | University Health Network, TorontoOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT01037790 | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | completed | Phase 2 | 304 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT02641691 | Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum(NORMAL-R) | completed | Phase 2 | 20 | Washington University School of MedicineOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT04508452 | A Phase II Prospective Trial of mXELOXIRI Reintroduction for mCRC | unknown | Phase 2 | 91 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT04621370 | A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer(PRIME-RT) | unknown | Phase 2 | 48 | Liz-Anne LewsleyOTHER | 0 | Nov 9, 2020 | clinicaltrials |
| NCT03152565 | Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer Patients(AVEVAC) | completed | Phase 1 / Phase 2 | 28 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | Oct 6, 2020 | clinicaltrials |
| NCT01367275 | Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF | terminated | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2020 | clinicaltrials |
| NCT00437268 | A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer | completed | Phase 2 | 26 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 21, 2020 | clinicaltrials |
| NCT04475159 | Combined Neoadjuvant Systemic and PIPAC Therapy (NASPIT) for Patients With Colorectal Peritoneal Metastasis Eligible for CRS and HIPEC: A Prospective Phase II Trial | unknown | Phase 2 | 50 | Prof. Aviram NissanOTHER_GOV | 0 | Jul 17, 2020 | clinicaltrials |
| NCT02652702 | Study Comparing Circular Stapler-assisted Colostomy vs Hand-stitching Colostomy of Colorectal Cancer Patients(STAPLER) | terminated | Phase 2 | 60 | Zhejiang UniversityOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04380103 | A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 106 | Chinese Academy of Medical SciencesOTHER | 1 | May 8, 2020 | clinicaltrials |
| NCT01674309 | First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis | completed | Phase 2 | 65 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Mar 30, 2020 | clinicaltrials |
| NCT02161822 | Capecitabine Plus Simvastatin in Locally Advanced Rectal Cancer Patients | unknown | Phase 2 | 60 | Samsung Medical CenterOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT02425683 | Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX | terminated | Phase 2 | 24 | US Oncology ResearchINDUSTRY | 1 | Feb 10, 2020 | clinicaltrials |
| NCT01802320 | Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Sep 20, 2019 | clinicaltrials |
| NCT00397878 | AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2019 | clinicaltrials |
| NCT02973672 | Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas | completed | Phase 1 / Phase 2 | 75 | SurgimabINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT01047969 | Avoiding Surgery in Rectal Cancer After Pre-Operative Therapy | unknown | Phase 2 | 99 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 13, 2019 | clinicaltrials |
| NCT00321685 | Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Mar 27, 2019 | clinicaltrials |
| NCT00409994 | Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer | completed | Phase 1 / Phase 2 | 44 | Maastricht Radiation OncologyOTHER | 1 | Mar 18, 2019 | clinicaltrials |
| NCT03823079 | Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia | unknown | Phase 2 | 50 | Fudan UniversityOTHER | 0 | Jan 30, 2019 | clinicaltrials |
| NCT02669914 | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | terminated | Phase 2 | 4 | Washington University School of MedicineOTHER | 1 | Nov 6, 2018 | clinicaltrials |
| NCT01037049 | Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks | unknown | Phase 2 | 237 | Royal Marsden NHS Foundation TrustOTHER | 4 | Sep 17, 2018 | clinicaltrials |
| NCT02216149 | Effects of S-1 and Capecitabine on Coronary Artery Blood Flow(FluoHeart) | terminated | Phase 2 | 20 | Heikki JoensuuOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT02508077 | FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Aug 16, 2018 | clinicaltrials |
| NCT02919878 | Neo-adjuvant Chemoradiotherapy Using Infusional Gemcitabine Followed by Surgery for Locally Advanced Rectal Cancer | unknown | Phase 2 | 25 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Aug 13, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Oct 6, 2022source: clinicaltrials